Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › EECOH-1

EECOH-1

Ecnoglutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ecnoglutide
Population
t2d
Phase
3
Participants
211
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
0.6 mgt2d china24211——−4.5 % vs −2.0 %
estimand not specified
−2.0 vs −0.91.4 vs 1.44.3 vs 2.87.2 vs 9.9—2.9 vs 5.6—press release
ecnoglutide 1.2 mgt2d china2471—−4.7 % vs −2.0 %
Δ −2.7 pp
−2.4 vs −0.91.4 vs 1.45.6 vs 2.812.7 vs 9.9—4.2 vs 5.6−5.2 vs −2.1verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (13)
  • 0.6 mg · hba1c · press release
    HbA1c change from baseline | -0.87 % | -1.96% ( P =0.0003) | -2.43% ( P< 0.0001)
  • 0.6 mg · weight_unsp · press release
    Percent body weight change from baseline | -2.02 % | -4.51% ( P =0.0002) | -4.74% ( P< 0.0001)
  • 0.6 mg · ae_dc · press release
    A total of three subjects, one (1.4%) from each cohort, discontinued the study due to adverse events.
  • 0.6 mg · disc_any · Results, para 1
    and safety set, and 9 (4%) of them discontinued treatment prematurely in the double-blind period, including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group (r
  • 0.6 mg · nausea · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
    Nausea 9 (12.7) 5 (7.2) 7 (9.9)
  • 0.6 mg · sae · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
    Serious TEAEs 3 (4.2) 2 (2.9) 4 (5.6)
  • ecnoglutide 1.2 mg · weight_tp · Results, Secondary outcomes; Table 2
    −4.74% (−5.65 to −3.82) with 1.2 mg ecnoglutide
  • ecnoglutide 1.2 mg · ae_dc · Results, Safety outcomes; Table 3
    TEAEs led to premature treatment discontinuation in 1 (1.4%) participant in each treatment group (Table 3).
  • ecnoglutide 1.2 mg · disc_any · Results, Study participants (denominator 71 from Table 3/Fig
    including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group
  • ecnoglutide 1.2 mg · nausea · Table 3
    Nausea 9 (12.7) 5 (7.2) 7 (9.9)
  • ecnoglutide 1.2 mg · sae · Results, Safety outcomes; Table 3
    Serious TEAEs were reported in 2.9% (2/69) of the 0.6 mg ecnoglutide group, 4.2% (3/71) of the 1.2 mg ecnoglutide group, and 5.6% (4/71) of the placebo group.
  • ecnoglutide 1.2 mg · hba1c · Results, Primary outcome; Table 2
    −2.43% (−2.65 to −2.20) with 1.2 mg ecnoglutide
  • ecnoglutide 1.2 mg · sbp · Results, Safety outcomes
    a mean of 5.2 mmHg with 1.2 mg ecnoglutide

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: EECOH-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.